The estimated Net Worth of Barry J. Simon is at least $107 million dollars as of 5 February 2021. Barry Simon owns over 22,100 units of NantKwest Inc stock worth over $103,728,874 and over the last 9 years he sold NK stock worth over $3,277,352. In addition, he makes $454,440 as President, Chief Administrative Officer et Director at NantKwest Inc.
Sign up
Barry Simon NK stock SEC Form 4 insiders trading
Barry has made over 14 trades of the NantKwest Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 22,100 units of NK stock worth $44,200 on 5 February 2021.
The largest trade he's ever made was selling 200,041 units of NantKwest Inc stock on 19 June 2020 worth over $2,112,433. On average, Barry trades about 62,863 units every 106 days since 2015. As of 5 February 2021 he still owns at least 3,192,640 units of NantKwest Inc stock.
You can see the complete history of Barry Simon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Barry Simon biography
Dr. Barry J. Simon, M.D. serves as President, Chief Administrative Officer, Director of the Company. He has served as a member of our board of directors since 2007 and as our President and Chief Administrative Officer since January 2017 and President and Chief Operating Officer from March 2015 to December 2016. From 2007 to March 2015, Dr. Simon was also our President and Chief Executive Officer. He also serves as a Director for Viracta Therapeutics, a biopharmaceutical company since July 2017 and as Chairman of the Compensation Committee for Viracta Therapeutics since April 2020, as Chairman of the Board for Cue BioPharma, a biopharmaceutical company since March 2016 and as President, CEO and Chairman for Brink Biologics Inc., a bioanalytics, reagents and testing services company, since March 2015. Previously, Dr. Simon held Vice President, senior level and advisory positions at F. Hoffmann-La Roche, a global healthcare company, Roche Labs, a pharmaceuticals company, Connetics Corporation, a specialty pharmaceutical company, Immunomedics, a biopharmaceutical company, Immusol, a biopharmaceutical company, HealthPro BioVentures, LLC, a healthcare and life sciences investment bank and NorthSound Capital, LLC, a U.S.-based hedge fund. Dr. Simon has broad experience in the public and private settings, having led private and public equity offerings, product and portfolio divestitures and acquisitions, strategic licensing and joint ventures, as well as commercial product launches, IND and BLA regulatory filings, human-enabling programs, manufacturing, quality control and life cycle management. Dr. Simon worked across several therapeutic areas including oncology, virology, ophthalmology and dermatology on products launches including Xeloda®, Pegasys®, Fortovase®, Tamiflu®, Camptobell®, Boniva®, Fuzeon®, Valcyt®, and Accutane. Dr. Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College.
What is the salary of Barry Simon?
As the President, Chief Administrative Officer et Director of NantKwest Inc, the total compensation of Barry Simon at NantKwest Inc is $454,440. There are no executives at NantKwest Inc getting paid more.
How old is Barry Simon?
Barry Simon is 55, he's been the President, Chief Administrative Officer et Director of NantKwest Inc since 2017. There are 4 older and 3 younger executives at NantKwest Inc. The oldest executive at NantKwest Inc is Frederick Driscoll, 69, who is the Lead Independent Director.
What's Barry Simon's mailing address?
Barry's mailing address filed with the SEC is C/O NANTKWEST, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121.
Insiders trading at NantKwest Inc
Over the last 9 years, insiders at NantKwest Inc have traded over $20,345,739 worth of NantKwest Inc stock and bought 4,163,265 units worth $55,365,252 . The most active insiders traders include Patrick Cambridge Equities,..., Steve Gorlin et Barry J. Simon. On average, NantKwest Inc executives and independent directors trade stock every 33 days with the average trade being worth of $5,362,832. The most recent stock trade was executed by Richard Adcock on 5 February 2021, trading 150,000 units of NK stock currently worth $4,873,500.
What does NantKwest Inc do?
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
What does NantKwest Inc's logo look like?
Complete history of Barry Simon stock trades at NantKwest Inc et Cue Biopharma Inc
NantKwest Inc executives and stock owners
NantKwest Inc executives and other stock owners filed with the SEC include:
-
Barry Simon,
President, Chief Administrative Officer, Director -
Sonja Nelson,
Chief Financial Officer -
Cheryl Cohen,
Director -
Patrick Soon-Shiong,
Executive Chairman of the Board -
Frederick Driscoll,
Lead Independent Director -
John Thomas,
Independent Director -
Michael Blaszyk,
Independent Director -
Richard Adcock,
Chief Executive Officer -
John T Jr Potts,
Director -
Richard Kusserow,
Director -
Angela Wilson,
Chief Financial Officer -
Steve Gorlin,
Director -
Richard J. Tajak,
Chief Financial Officer -
Patrickmp 13 Ventures, Llc ...,
Chairman and CEO -
Patrick Chan Soon Shiong Fa...,
Chairman and CEO